Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
5 search results for:

Verinurad 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-04-2018 | Gout | Highlight | Teaser
    medwireNews editor's pick

    Verinurad–febuxostat combination shows promise for the treatment of gout

    Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

  2. 23-04-2018 | Gout | News | Article

    Verinurad–febuxostat combination shows promise for the treatment of gout

    Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

    Published in:
    RMD Open 2018; 4 : e000647
  3. 01-06-2018 | Gout | Article

    Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricemia: A phase 2a, open-label study

    Shiramoto M et al. Rheumatology (Oxford) 2018: key100. doi: 10.1093/rheumatology/key100

  4. 06-06-2018 | Gout | News | Article

    Phase II results support extended-release febuxostat in gout patients with renal impairment

    . © 2018 Springer Healthcare part of the Springer Nature group See also: Verinurad–febuxostat combination shows promise for the treatment of gout FDA announces febuxostat safety alert CARES trial published: Increased cardiovascular death risk with febuxostat

    Published in:
    Arthritis Res Ther 2018; 20 : 99
  5. 30-10-2017 | Gout | Editorial | Article

    Evolution or revolution in urate-lowering therapies for gout?

    For example, febuxostat and topiroxostat are potent, specific inhibitors of xanthine oxidase, pegloticase is an uricolytic medication, and verinurad is to date the most potent URAT1 inhibitor to be tested in clinical trials [9].

    Author:
    Fernando Pérez-Ruiz
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.